臺灣博碩士論文加值系統

A型血友病(Hemophilia A)是一種因血液凝固機制發生異常的遺傳性出血性疾病，主要是因為人類第八凝血因子(human factor VIII, hFVIII)的缺乏所導致，目前醫療技術無法完全根治，必須長期接受治療。現今研究是以基因轉殖工程技術讓生物反應器(bioreactors)製備非血液純化的hFVIII。主要為利用動物細胞株，例如倉鼠卵巢細胞株(Chinese hamster ovary cells, CHO cells)或倉鼠腎細胞株(Baby hamster kidney cells, BHK cells)製備重組hFVIII，然而培養槽容納細胞數量有限，提升規模所需費用昂貴導致成本過高。若選用基因轉殖動物，例如豬或牛來製備重組hFVIII，飼育時間則過於冗長，也相對提高成本。而斑馬魚生命週期較短、產卵數多，在控溫情況下終年可產卵，加上基因轉殖技術容易，養殖所需設備簡單成本便宜。因此本研究欲使用斑馬魚當作bioreactor，於斑馬魚體內及魚卵中製備重組hFVIII。本研究首先構築分別由zebrafish hsp 70/4 promoter或zebrafish a-tubulin promoter或CMV promoter來驅動移除了釋泌訊息胜肽(signal peptide)與hFVIII B domain的hBDD-FVIII基因片段或hBDD-FVIII-EGFP基因片段。接著將CMV promoter驅動hBDD-FVIII基因片段的表現載體透過細胞轉染到HEK293T細胞株中，用Western blot偵測表現的細胞株蛋白質，可偵測到接近170 KDa大小左右的hBDD-FVIII重組蛋白質。發現移除了signal peptide與B domain的hBDD-FVIII仍可以在哺乳類動物細胞株內表現。然後藉由顯微注射將zebrafish hsp 70/4 promoter與zebrafish a-tubulin promoter驅動hBDD-FVIII基因片段或hBDD-FVIII-EGFP基因片段的表現載體轉殖到斑馬魚胚胎中，並利用綠螢光表現有無篩選可能基因轉殖品系G0親代。其中由zebrafish hsp 70/4 promoter驅動hBDD-FVIII基因片段的基因轉殖斑馬魚G0親代已達性成熟，育成後與野生型斑馬魚配對，挑選子代有綠螢光表現的基因轉殖品系G0親代，並利用PCR檢測基因轉殖品系其F1子代胚胎的genomic DNA，可以偵測到約為預期547 bp大小的hBDD-FVIII外源基因片段訊號。目前篩選出9隻基因轉殖斑馬魚G0其子代有綠螢光表現並且genomic DNA中確認帶有hBDD-FVIII外源基因片段，將這9隻基因轉殖斑馬魚G0與野生型斑馬魚配對並收集有綠螢光表現的F1子代胚胎進行飼育。之後進一步收集25隻基因轉殖品系其F1子代胚胎進行熱誘導處理，透過RT-PCR檢測熱誘導處理後基因轉殖品系G0其F1子代胚胎的mRNA，同樣可以偵測到如預期547 bp大小的hBDD-FVIII外源基因片段訊號。本研究確認基因轉殖斑馬魚品系其F1子代胚胎經由熱誘導處理後，hBDD-FVIII外源基因片段不僅在genomic DNA中順利遺傳，在RNA層次上hBDD-FVIII外源基因片段也能藉由熱誘導處理後順利轉錄成hBDD-FVIII mRNA。然而利用Western blot偵測熱誘導處理之基因轉殖品系其F1子代胚胎全蛋白，以人類FVIII heavy chain抗體並未偵測到訊號，顯示在蛋白質層次上，hBDD-FVIII外源基因片段於熱誘導處理後並未能順利轉譯出hBDD-FVIII重組蛋白質。

Hemophilia A is an X-linked, recessive bleeding disorder, which is caused by the defective human coagulation factor VIII (hFVIII). At the present time, Hemophilia A patients are treated with recombinant hFVIII produced by chinese hamster ovary (CHO) cells or baby hamster kidney (BHK) cells. However, it is very costly. In this study, we attempted to use zebrafish (Danio rerio) as a bioreactor to produce recombinant hFVIII because of short generation time, high fecundity, simple and cheap culture system, and easy manipulation of gene transfer. We constructed an expression plasmid, in which B domain-deleted hFVIII (hBDD-FVIII) was driven by either CMV promoter. After HEK293T cells were transfected with pCMV-BDFVIII, the total extracted proteins were subjected to western blot analysis using antiserum against hFVIII heavy chain. Results showed that there was a positive band located at 170 kDa, which was corresponding to the recombinant hBDD-FVIII protein. Other expression plasmids pHBDFVIII, pHBDFVIII-EGFP and pZaBDFVIII-EGFP were also constructed, in which either hBDD-FVIII or hBDD-FVIII-EGFP was driven by zebrafish hsp 70/4 promoter or zebrafish a-tubulin promoter, and microinjected into one-celled zebrafish embryos individually. In total, nine G0 lines harboring pHBDFVIII were generated. We extracted genomic DNA from F1 embryos and detected by PCR. A 547 bp PCR-product was amplified and corresponded with the amplification of partial hFVIII A3 domain from transgene. We also extracted total RNA from F1 embryos treated by heat-shock treatment and detected by RT-PCR. A 547 bp PCR-product was also amplified and corresponded with the amplification of transgene, suggesting that these lines can transcribe the recombinant B domain-deleted human factor VIII transgene after induction. Furthermore, the total proteins that were extracted from F1 embryos treated by heat-shock treatment were subjected to western blot analysis using antiserum against hFVIII heavy chain. However, results showed that there was no signal corresponding to the recombinant hBDD-FVIII protein. It suggested that these lines can not translate the recombinant B domain-deleted human factor VIII protein after induction.

中文摘要 - 1
英文摘要 - 3
文獻回顧 - 5
前言 - 11
實驗材料與方法 - 14
結果 - 26
討論 - 30
參考文獻 - 33
圖表 - 43
附錄：Developmental stages in the zebrafish - 49

Andersen, D.C. and Krummen, L. (2002). Recombinant protein expression for therapeutic applications. Curr Opin Biotechnol 13, 117-123.

Brem, G., Hartl, P., Besenfelder, U., Wolf, E., Zinovieva, N., and Pfaller, R. (1994). Expression of synthetic cDNA sequences encoding human insulin-like growth factor-1 (IGF-1) in the mammary gland of transgenic rabbits. Gene 149, 351-355.

Burnouf, T. (2011). Recombinant plasma proteins. Vox Sang 100, 68-83.

Chen, C.M., Wang, C.H., Wu, S.C., Lin, C.C., Lin, S.H., and Cheng, W.T.K. (2002). Temporal and spatial expression of biologically active human factor VIII in the milk of transgenic mice driven by mammary-specific bovine a-lactalbumin regulation sequences. Transgenic Res 11, 257-268.

Clements, J.E., Wall, R.J., Narayan, O., Hauer, D., Schoborg, R., Sheffer, D., Powell, A., Carruth, L.M., Zink, M.C., and Rexroad, C.E. (1994). Development of transgenic sheep that express the visna virus envelope gene. Virology 200, 370-380.

Connelly, S., Andrews, J.L., Gallo, A.M., Kayda, D.B., Qian, J., Hoyer, L., Kadan, M.J., Gorziglia, M.I., Trapnell, B.C., McClelland, A., and Kaleko, M. (1998). Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood 91, 3273-3281.

Dahlbäck, B. (2000). Blood coagulation. Lancet 355, 1627-1632.

Doering, C.B., Healey, J.F., Parker, E.T., Barrow, R.T., and Lollar, P. (2002). High level expression of recombinant porcine coagulation factor VIII. J Biol Chem 277, 38345-38349.

Driever, W., Solnica-Krezel, L., Schier, A.F., Neuhauss, S.C.F., Malicki, J., Stemple, D.L., Stainier, D.Y.R., Zwartkruis, F., Abdelilah, S., Rangini, Z., Belak, J., and Boggs, C. (1996). A genetic screen for mutations affecting embryogenesis in zebrafish. Development 123, 37-46.

Dyck, M.K., Lacroix, D., Pothier, F., and Sirard, M.A. (2003). Making recombinant proteins in animals - different systems, different applications. Trends Biotechnol 21, 394-399.

Eaton, D.L., Hass, P.E., Riddle, L., Mather, J., Wiebe, M., Gregory, T., and Vehar G.A. (1987). Characterization of recombinant human factor VIII. J Biol Chem 262, 3285-3290.

Eaton, D.L., Rodriguez, H., and Vehar, G.A. (1986). Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 25, 505-512.

Fay, P.J. (2004). Activation of factor VIII and mechanisms of cofactor action. Blood Rev 18, 1-15.

Fay, P.J., Anderson, M.T., Chavin, S.I., and Marder, V.J. (1986). The size of human factor VIII heterodimers and the effects produced by thrombin. Biochim Biophys Acta 871, 268-278.

Fay, P.J., Haidaris, P.J., and Smudzin, T.M. (1991). Human factor VIIIa subunit structure. Reconstruction of factor VIIIa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 266, 8957-8962.

Gordon, K., Lee, E., Vitale, J.A., Smith, A.E., Westphal, H., and Hennighausen, L. (1987). Production of human tissue plasminogen activator in transgenic mouse milk. Nat Biotechnol 5, 1183-1187.

Heinz, S., Schüttrumpf, J., Simpson, J.C., Pepperkok, R., Nicolaes, G.A., Abriss, D., Milanov, P., Roth, S., Seifried, E., and Tonn, T. (2009). Factor VIII-eGFP fusion proteins with preserved functional activity for the analysis of the early secretory pathway of factor VIII. Thromb Haemost 102, 925-935.

Houdebine, L.M. (2000). Transgenic animal bioreactors. Transgenic Res 9, 305-320.

Hoyer, L.W. (1994). Hemophilia A. N Engl J Med 330, 38-47.

Hoyer, L.W. (1981). The factor VIII complex: structure and function. Blood 58, 1-13.

Hu, S.Y., Liao, C.H., Lin, Y.P., Li, Y.H., Gong, H.Y., Lin, G.H., Kawakami, K., Yang, T.H., and Wu, J.L. (2011). Zebrafish eggs used as bioreactors for the production of bioactive tilapia insulin-like growth factors. Transgenic Res 20, 73-83.

Hwang, G., Müller, F., Rahman, M.A., Williams, D.W., Murdock, P.J., Pasi, K.J., Goldspink, G., Farahmand, H., and Maclean, N. (2004). Fish as bioreactors: transgene expression of human coagulation factor VII in fish embryos. Mar Biotechnol 6, 485-492.

Kao, C.L. (2009). Zebrafish as a bioreactor to produce recombinant pathogen-resistant proteins. 國立臺灣大學生命科學院分子與細胞生物學研究所碩士論文.

Kimmel, C.B., Ballard, W.W., Kimmel, S.R., Ullmann, B., and Schilling, T.F. (1995). Stage of embryonic development of the zebrafish. Dev Dyn 203, 253-310.

Larrick, J.W. and Thomas, D.W. (2001). Producing proteins in transgenic plants and animals. Curr Opin Biotechnol 12, 411-418.

Lee, C.A., Berntorp, E.E., and Hoots, W.K. (2010). Textbook of Hemophilia 2, 1-476.

Lin, C.Y., Yang, P.H., Kao, C.L., Huang, H.I., and Tsai, H.J. (2010). Transgenic zebrafish eggs containing bactericidal peptide is a novel food supplement enhancing resistance to pathogenic infection of fish. Fish Shellfish Immunol 28, 419-427.

Lind, P., Larsson, K., Spira, J., Sydow-Bäckman, M., Almstedt, A., Gray, E., and Sandberg, H. (1995). Novel forms of B-domain-deleted recombinant factor VIII molecules construction and biochemical characterization. Eur J Biochem 232, 19-27.

Lo, D., Pursel, V., Linton, P.J., Sandgren, E., Behringer, R., Rexroad, C., Palmiter, R.D., and Brinster, R.L. (1991). Expression of mouse IgA by transgenic mice, pigs and sheep. Eur J Immunol 21, 1001-1006.

Lollar, P., Hill-Eubanks, D.C., and Parker, C.G. (1988). Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 263, 10451-10455.

Luboń, H., Paleyanda, R.K., Velander, W.H., and Drohan, W.N. (1996). Blood proteins from transgenic animal bioreactors. Transfus Med Rev 10, 131-143.

Mann, K.G. (1999). Biochemistry and physiology of blood coagulation. Thromb Haemost 82, 165-174.

Miao, H.Z., Sirachainan, N., Palmer, L., Kucab, P., Cunningham, M.A., Kaufman, R.J., and Pipe, S.W. (2004). Bioengineering of coagulation factor VIII for improved secretion. Blood 103, 3412-3419.

Morita, T., Yoshizaki, G., Kobayashi, M., Watabe, S., and Takeuchi, T. (2004). Fish eggs as bioreactors: the production of bioactive luteinizing hormone in transgenic trout embryos. Transgenic Res 13, 551-557.

Nesheim, M., Pittman, D.D., Giles, A.R., Fass, D.N., Wang, J.H., Slonosky, D., and Kaufman, R.J. (1991). The effect of plasma von Willebrand factor on the binding of human factor VIII to thrombin-activated human platelets. J Biol Chem 266, 17815-17820.

O’Brien, L.M., Medved, L.V., and Fay, P.J. (1995). Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem 270, 27087-27092.

Paleyanda, R.K., Velander, W.H., Lee, T.K., Scandella, D.H., Gwazdauskas, F.C., Knight, J.W., Hoyer, L.W., Drohan, W.N., and Luboń, H. (1997). Transgenic pigs produce functional human factor VIII in milk. Nat Biotechnol 15, 971-975.

Pipe, S.W. (2009). Functional roles of the factor VIII B domain. Haemophilia 15, 1187-1196.

Pipe, S.W. (2008). Recombinant clotting factors. Thromb Haemost 99, 840-850.

Pipe, S.W., High, K.A., Ohashi, K., Ural, A.U., and Lillicrap, D. (2008). Progress in the molecular biology of inherited bleeding disorders. Haemophilia 14, 130-137.

Pipe, S.W. and Kaufman, R.J. (2000). A chamber of hope for hemophilia. Nat Biotechnol 18, 264-265.

Pittman, D.D., Alderman, E.M., Tomkinson, K.N., Wang, J.H., Giles, A.R., and Kaufman R.J. (1993). Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 81, 2925-2935.

Pittman, D.D. and Kaufman, R.J. (1988). Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci USA 85, 2429-2433.

Pittman, D.D., Marquette, K.A., and Kaufman, R.J. (1994). Role of the B domain for factor VIII and factor V expression and function. Blood 84, 4214-4225.

Pursel, V.G. and Rexroad C.E.Jr. (1993). Status of research with transgenic farm animals. J Anim Sci 71, 10-19.

Rocha, A., Ruiz, S., Estepa, A., and Coll, J.M. (2004). Application of inducible and targeted gene strategies to produce transgenic fish: a review. Mar Biotechnol 6, 118-127.

Salamone, D., Barañao, L., Santos, C., Bussmann, L., Artuso, J., Werning, C., Prync, A., Carbonetto, C., Dabsys, S., Munar, C., Salaberry, R., Berra, G., Berra, I., Fernández, N., Papouchado, M., Foti, M., Judewicz, N., Mujica, I., Muñoz, L., Alvarez, S.F., González, E., Zimmermann, J., Criscuolo, M., and Melo, C. (2006). High level expression of bioactive recombinant human growth hormone in the milk of a cloned transgenic cow. J Biotechnol 124, 469-472.

Schenone, M., Furie, B.C., and Furie, B. (2004). The blood coagulation cascade. Curr Opin Hematol 11, 272-277.

Shoji, W. and Sato-Maeda, M. (2008). Application of heat shock promoter in transgenic zebrafish. Dev Growth Differ 50, 401-406.

Simons, J.P., McClenaghan, M., and Clark, A.J. (1987). Alteration of the quality of milk by expression of sheep b-lactoglobulin in transgenic mice. Nature 328, 530-532.

Simons, J.P., Wilmut, I., Clark, A.J., Archibald, A.L., Bishop, J.O., and Lathe, R. (1988). Gene transfer into sheep. Nat Biotechnol 6, 179-183.

Solomon, M.B., Pursel, V.G., Paroczay, E.W., and Bolt, D.J. (1994). Lipid composition of carcass tissue from transgenic pigs expressing a bovine growth hormone gene. J Anim Sci 72, 1242-1246.

Soukharev, S., Hammond, D., Ananyeva, N.M., Anderson, J.A.M., Hauser, C.A.E., Pipe, S., and Saenko, E.L. (2002). Expression of factor VIII in recombinant and transgenic systems. Blood Cell Mol Dis 28, 234-248.

Swartz, J.R. (2001). Advances in Escherichia coli production of therapeutic proteins. Curr Opin Biotechnol 12, 195-201.

Thim, L., Vandahl, B., Karlsson, J., Klausen, N.K., Pedersen, J., Krogh, T.N., Kjalke, M., Petersen, J.M., Johnsen, L.B., Bolt, G., Nørby, P.L., and Steenstrup, T.D. (2009). Purification and characterization of a new recombinant factor VIII (N8). Haemophilia 16, 349-359.

Toole, J.J., Knopf, J.L., Wozney, J.M., Sultzman, L.A., Buecker, J.L., Pittman, D.D., Kaufman, R.J., Brown, E., Shoemaker, C., Orr, E.C., Amphlett, G.W., Foster, W.B., Coe, M.L., Knutson, G.J., Fass, D.N., and Hewick, R.M. (1984). Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312, 342-347.

Tuddenham, E.G.D. (1989). Factor VIII and haemophilia A. Bailliére’s Clin Haematol 2, 849-877

Vehar, G.A., Keyt, B., Eaton, D., Rodriguez, H., O’Brien, D.P., Rotblat, F., Oppermann, H., Keck, R., Wood, W.I., Harkins, R.N., Tuddenham, E.G.D., Lawn, R.M., and Capon, D.J. (1984). Structure of human factor VIII. Nature 312, 337-342.

Wakabayashi, H., Varfal, F., DeAngelis, J., and Fay, P.J. (2008). Generation of enhanced stability factor VIII variants by replacement of charged residues at the A2 domain interface. Blood 112, 2761-2769.

Wang, D., Liu, W., Han, B., and Xu, R. (2005). The bioreactor: a powerful tool for large-scale culture of animal cells. Curr Pharm Biotechnol 6, 397-403.

Weidle, U.H., Lenz, H., and Brem, G. (1991). Genes encoding a mouse monoclonal antibody are expressed in transgenic mice, rabbits and pigs. Gene 98, 185-191.

Williams, D.C., Van Frank, R.M., Muth, W.L., and Burnett, J.P. (1982). Cytoplasmic inclusion bodies in Escherichia coli producing biosynthetic human insulin proteins. Science 215, 687-689.

Wise, R.J., Dorner, A.J., Krane, M., Pittman, D.D., and Kaufman, R.J. (1991). The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem 266, 21948-21955.

Yang, P.H. (2008). Zebrafish as bioreactors to produce recombinant protein. 國立臺灣大學生命科學院分子與細胞生物學研究所碩士論文.

Zbikowska, H.M. (2003). Fish can be first - advances in fish transgenesis for commercial applications. Transgenic Res 12, 379-389.

Zhang, Y.C., Zhou, Y., Yang, C.Z., and Xiong, D.S. (2009). A review of ERGIC-53: its structure, functions, regulation and relations with diseases. Histol Histopathol 24, 1193-1204.